The webinar will feature a presentation by Key Opinion Leader (KOL) Mark Ryder, M.D. (University of California, San Francisco). On July 23, in conjunction with the International Association for Dental Research (IADR) conference, Cortexyme will present abstract #3571509 entitled “Gingipain Inhibitors Penetrate and Inhibit Gingipains In Porphyromonas gingivalis Biofilms” and abstract #1756 entitled “Novel Lysine-Gingipain Inhibitor Atuzaginstat (COR388) Is Efficacious in a Mouse Model of Periodontal Disease.” During the webinar on July 23, Dr. Ryder will address these abstracts as well as discuss the current landscape and unmet medical need in treating patients with P. gingivalis-induced periodontal disease. Dr. Ryder and Cortexyme management will be available to answer questions following the formal presentations.

Cortexyme’s management team will also give an update on its pipeline candidate, COR588, a unique small molecule lysine gingipain inhibitor with once-daily oral dosing. Top-line data from the 233-subject REPAIR Periodontal Phase 2 sub-study as part of the Phase 2/3 GAIN trial is expected in Q4 2021.